24866 Federal Register / Vol. 60, No. 90 / Wednesday, May 10, 1995 / Notices

under section 4(c)(8) of the Bank

Holding Company Act (12 U.S.C.

1843(c)(8)) and § 225.21(a) of Regulation

Y (12 CFR 225.21(a)) to commence or to

engage de novo, either directly or

through a subsidiary, in a nonbanking

activity that is listed in § 225.25 of

Regulation Y as closely related to

banking and permissible for bank

holding companies. Unless otherwise

noted, such activities will be conducted

throughout the United States.

The application is available for

immediate inspection at the Federal

Reserve Bank indicated. Once the

application has been accepted for

processing, it will also be available for

inspection at the offices of the Board of

Governors. Interested persons may

express their views in writing on the

question whether consummation of the

proposal can ‘‘reasonably be expected to

produce benefits to the public, such as

greater convenience, increased

competition, or gains in efficiency, that

outweigh possible adverse effects, such

as undue concentration of resources,

decreased or unfair competition,

conflicts of interests, or unsound

banking practices.’’ Any request for a

hearing on this question must be

accompanied by a statement of the

reasons a written presentation would

not suffice in lieu of a hearing,

identifying specifically any questions of

fact that are in dispute, summarizing the

evidence that would be presented at a

hearing, and indicating how the party

commenting would be aggrieved by

approval of the proposal.

Comments regarding the application

must be received at the Reserve Bank

indicated or the offices of the Board of

Governors not later than May 24, 1995.

A. Federal Reserve Bank of Chicago

(James A. Bluemle, Vice President) 230

South LaSalle Street, Chicago, Illinois

60690:

1. AMCORE Financial Inc., Rockford,

Illinois; to acquire Rockford Mercantile

Agency, Inc., Rockford, Illinois, and

thereby engage de novo in check

guarantee services, pursuant to

§ 225.25(b)(22), and rental or sale of

related equipment, pursuant to

§ 225.25(b)(7) of the Board’s Regulation

Y.

Board of Governors of the Federal Reserve

System, May 4, 1995.

William W. Wiles,

Secretary of the Board.

[FR Doc. 95–11473 Filed 5–9–95; 8:45 am]

BILLING CODE 6210–01–F

Mason-Dixon Bancshares, Inc., et al.;

Formations of; Acquisitions by; and

Mergers of Bank Holding Companies

The companies listed in this notice

have applied for the Board’s approval

under section 3 of the Bank Holding

Company Act (12 U.S.C. 1842) and §

225.14 of the Board’s Regulation Y (12

CFR 225.14) to become a bank holding

company or to acquire a bank or bank

holding company. The factors that are

considered in acting on the applications

are set forth in section 3(c) of the Act

(12 U.S.C. 1842(c)).

Each application is available for

immediate inspection at the Federal

Reserve Bank indicated. Once the

application has been accepted for

processing, it will also be available for

inspection at the offices of the Board of

Governors. Interested persons may

express their views in writing to the

Reserve Bank or to the offices of the

Board of Governors. Any comment on

an application that requests a hearing

must include a statement of why a

written presentation would not suffice

in lieu of a hearing, identifying

specifically any questions of fact that

are in dispute and summarizing the

evidence that would be presented at a

hearing.

Unless otherwise noted, comments

regarding each of these applications

must be received not later than June 5,

1995.

A. Federal Reserve Bank of

Richmond (Lloyd W. Bostian, Jr., Senior

Vice President) 701 East Byrd Street,

Richmond, Virginia 23261:

1. Mason-Dixon Bancshares, Inc.,

Westminster, Maryland; to acquire 100

percent of the voting shares of Bank

Maryland Corp., Towson, Maryland,

and thereby indirectly acquire Bank of

Maryland, Towson, Maryland.

B. Federal Reserve Bank of Dallas

(Genie D. Short, Vice President) 2200

North Pearl Street, Dallas, Texas 75201–

-2272:

1. SNB Corporation, Houston, Texas;

to become a bank holding company by

acquiring 100 percent of the voting

shares of Southern National Bank of

Texas, Houston, Texas.

2. SNB Bancshares, Inc., Houston,

Texas; to become a bank holding

company by acquiring 100 percent of

the voting shares of SNB Corporation,

Wilmington, Delaware, and thereby

indirectly acquire Southern National

Bank of Texas, Houston, Texas.

In connection with this application,

SNB Corporation, Houston, Texas, also

has applied to become a bank holding

company.

Board of Governors of the Federal Reserve

System, May 4, 1995.

William W. Wiles,

Secretary of the Board.

[FR Doc. 95–11474 Filed 5–9–95; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Agency for Health Care Policy and

Research

Meetings

In accordance with section 10(a) of

the Federal Advisory Committee Act (5

U.S.C., Appendix 2) announcement is

made of the following advisory

committees scheduled to meet during

the month of June 1995:

Name: Health Services Developmental

Grants Review Subcommittee.

Date and Time: June 7–8, 1995, 8:00 a.m.

Place: Holiday Inn Crowne Plaza, 1750

Rockville Pike, Conference Room TBA,

Rockville, Maryland 20852

Open June 7, 8:00 a.m. to 9:00 a.m.

Closed for remainder of meeting.

Purpose: The Subcommittee is charged

with the initial review of grant applications

proposing experimental, analytical and

theoretical research on costs, quality, access,

effectiveness, and efficiency of the delivery

of health services for the research grant

program administered by the Agency for

Health Care Policy and Research (AHCPR).

Agenda: The open session of the meeting

on June 7 from 8:00 a.m. to 9:00 a.m. will be

devoted to a business meeting covering

administrative matters and reports. During

the closed session, the Subcommittee will be

reviewing and discussing grant applications

dealing with health services research issues.

In accordance with the Federal Advisory

Committee Act, section 10(d) of 5 U.S.C.,

Appendix 2 and 5 U.S.C., 552b(c)(6), the

Administrator, Agency for Health Care Policy

and Research, has made a formal

determination that these latter sessions will

be closed because the discussions are likely

to reveal personal information concerning

individuals associated with the applications.

This information is exempt from mandatory

disclosure.

Anyone wishing to obtain a roster of

members, minutes of the meeting, or other

relevant information should contact J. Terrell

Hoffeld, D.D.S., Ph.D., Scientific Review

Administrator, Scientific Review Branch,

Agency for Health Care Policy and Research,

Suite 602, Executive Office Center, 2101 East

Jefferson Street, Rockville, Maryland 20852,

Telephone (301) 594–1449.

Name: Health Services Research Review

Subcommittee.

Date and Time: June 8–9, 1995, 8:00 a.m.

Place: Holiday Inn Crowne Plaza, 1750

Rockville Pike, Rockville, MD 20852.

Open June 8, 8:00 a.m. to 8:45 a.m.

Closed for remainder of meeting.

Purpose: The Subcommittee is charged

with the initial review of grant applications
Federal Register / Vol. 60, No. 90 / Wednesday, May 10, 1995 / Notices 24867

proposing analytical and theoretical research

on costs, quality, access, and efficiency of the

delivery of health services for the research

grant program administered by the Agency

for Health Care Policy and Research

(AHCPR).

Agenda: The open session of the meeting

on June 8 from 8:00 a.m. to 8:45 a.m. will be

devoted to a business meeting covering

administrative matters and reports. During

the closed sessions, the Subcommittee will

be reviewing and discussing grant

applications dealing with health services

research issues. In accordance with the

Federal Advisory Committee Act, section

10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C.

552b(c)(6), the Administrator, Agency for

Health Care Policy Research, has made a

formal determination that these latter

sessions will be closed because the

discussions are likely to reveal personal

information concerning individuals

associated with the applications. This

information is exempt from mandatory

disclosure.

Anyone wishing to obtain a roster of

members, minutes of the meeting, or other

relevant information should contact Patricia

G. Thompson, Ph.D., Scientific Review

Administrator, Scientific Review Branch,

Agency for Health Care Policy and Research,

Suite 602, Executive Office Center, 2101 East

Jefferson Street, Rockville, Maryland 20852,

Telephone (301) 594–1451.

Name: Health Care Technology Study

Section.

Date and Time: June 19–20, 1995, 8:00 a.m.

Place: Holiday Inn Crowne Plaza, 1750

Rockville Pike, Conference Room TBA,

Rockville, Maryland 20852.

Open June 19, 8:00 a.m. to 9:00 a.m.

Closed for remainder of meeting.

Purpose: The Study Section is charged

with conducting the initial review of health

services research grant applications

concerned with medical decisionmaking,

computers in health care delivery, and the

utilization and effects of health care

technologies and procedures.

Agenda: The open session on June 19 from

8:00 a.m. to 9:00 a.m. will be devoted to a

business meeting covering administrative

matters and reports. The closed session of the

meeting will be devoted to reviewing and

discussing grant applications dealing with

health services research issues. In accordance

with the Federal Advisory Committee Act,

Section 10(d) of 5 U.S.C., Appendix 2 and 5

U.S.C., 552b(c)(6), the Administrator, Agency

for Health Care for Policy and Research, has

made a formal determination that these latter

sessions will be closed because the

discussions are likely to reveal personal

information concerning individuals

associated with the applications. This

information is exempt from mandatory

disclosure.

Anyone wishing to obtain a roster of

members, minutes of the meeting, or other

relevant information should contact Karen

Rudzinski, Ph.D., Scientific Review

Administrator, Scientific Review Branch,

Agency for Health Care Policy and Research,

Suite 602, Executive Office Center, 2101 East

Jefferson Street, Rockville, Maryland 20852,

Telephone (301) 594–1437.

Name: Health Services Research

Dissemination Study Section.

Date and Time: June 29–30, 1995, 8:00 a.m.

Place: Chevy Chase Holiday Inn, 5520

Wisconsin Avenue, Palladian Room, Chevy

Chase, Maryland 20815.

Open June 29, 8:00 a.m. to 8:30 a.m.

Closed for remainder of meeting.

Purpose: The Study Section is charged

with the review of and making

recommendations on grant applications for

Federal support of conferences, workshops,

meetings, or projects related to dissemination

and utilization of research findings, and

AHCPR liaison with health care policy

makers, providers, and consumers.

Agenda: The open session of the meeting

on June 29 from 8:00 a.m. to 8:30 a.m. will

be devoted to general business matters.

During the closed portions of the meeting,

the Study Section will be reviewing and

discussing grant applications dealing with

health services research issues. In accordance

with the Federal Advisory Committee Act,

section 10(d) of 5 U.S.C., Appendix 2 and 5

U.S.C., 552b(c)(6), the Administrator, Agency

for Health Care Policy and Research, has

made a formal determination that these latter

sessions will be closed because the

discussions are likely to reveal personal

information concerning individuals

associated with the grant applications. This

information is exempt from mandatory

disclosure.

Anyone wishing to obtain a roster of

members, minutes of the meeting, or other

relevant information should contact Linda

Blankenbaker, Scientific Review

Administrator, Scientific Review Branch,

Agency for Health Care Policy and Research,

Suite 602, 2101 East Jefferson Street,

Rockville, Maryland 20852, Telephone (301)

594–1438.

Agenda items for all meetings are subject

to change as priorities dictate.

Dated: May 3, 1995.

Clifton R. Gaus,

Administrator.

[FR Doc. 95–11472 Filed 5–9–95; 8:45 am]

BILLING CODE 4160–90–M

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

HHS.

ACTION: Notice.

The inventions listed below are

owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of federally

funded research and development.

Foreign patent applications are filed on

selected inventions to extend market

coverage for U.S. companies and may

also be available for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated Licensing Specialist at

the Office of Technology Transfer,

National Institutes of Health, 6011

Executive Boulevard, Suite 325,

Rockville, Maryland 20852–3804

(telephone 301/496–7735; fax 301/402–

0220). A signed Confidential Disclosure

Agreement will be required to receive

copies of the patent applications.

2,5–Diamino-3,4–Disubstituted-1,6-FDiphenyhexane Isoteres Comprising

Benzamide, Sulfonamide and

Anthranilamide Subunits and Methods

Of Using Same

Randad, R.S., Erickson, J.W. (NCI)

Filed 20 Dec 94

Serial No. 08/359,612

Licensing Contact: Robert Benson (301/

496–7056 ext 267)

This invention concerns retroviral

protease inhibitors which are potential

drugs for the treatment of HIV infection.

The compounds of the invention

contain novel nonpeptidic and achiral

substituents, wherein achiral

benzamide, sulfonamide and

anthranilamide subunits are introduced

onto the 2,5-diamino-3,4-disubstituted1,6-diphenylhexane isostere core. The

compounds are more resistant to viral

and mammalian protease degradation.

The best compounds had a Ki

(inhibition constant) of less than 100

pM for HIV protease. CEM cells

chronically infected with HIV–1 were

used to test anti-retroviral activity. The

concentrations needed to inhibit 50% of

viral activity were on the order of 5 nM.

Therefore, these compounds compare

favorably in their anti-viral potency to

the best HIV protease inhibitors

currently in clinical trials. [portfolio:

Infectious Diseases—Therapeutics, antivirals, AIDS]

Conformationally Locked Nucleoside

Analogs

Marquez, V.E., Rodriguez, J.B., Nicklaus,

M.C., Barchi, J.J.

(NCI)

Filed 24 Sep 94

Serial No. 08/311,425 (CIP of 08/

126,796)

Licensing Contact: Carol Lavrich (301/

496–7735 ext 287)

Novel nucleoside analogues have

been developed that may facilitate

structure-function analysis of anti-HIV

compounds. Recently, there has been

intense interest in the design and use of

nucleoside analogues that can inhibit

the replication of viruses such as HIV–

1. The three-dimensional conformation

of such analogues has been implicated

in their ability to successfully inhibit

viral replication; however, in the past, it

has been difficult to conduct structure-